Rhythm Pharmaceuticals, Inc.
MX ˙ BMV ˙ US76243J1051
SecurityMX:RYTM / Rhythm Pharmaceuticals, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership1,818,931 shares
Ownership 3.00%
Goldman Sachs Group Inc ownership in RYTM / Rhythm Pharmaceuticals, Inc.

2025-02-10 - Goldman Sachs Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,818,931 shares of Rhythm Pharmaceuticals, Inc. (MX:RYTM). This represents 3.0 percent ownership of the company. In their previous filing dated 2024-11-12 , Goldman Sachs Group Inc had reported owning 3,891,020 shares, indicating a decrease of -53.25 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-02-10 2025-02-10 13G/A 3,891,020 1,818,931 -53.25 3.00 -53.13
2024-11-12 2024-11-12 13G/A 4,998,761 3,891,020 -22.16 6.40 -24.71
2024-02-05 2024-02-05 13G/A 5,201,260 4,998,761 -3.89 8.50 -7.61
2023-02-08 2023-02-08 13G/A 3,057,559 5,201,260 70.11 9.20 50.82
2022-01-24 2022-01-24 13G 3,057,559 6.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,965,432 134,566 7.35 170,934 -12.78 0.0046
2026-02-10 2025-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,830,866 -62,797 -3.32 195,976 2.48 0.0242
2025-11-14 2025-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,893,663 159,941 9.23 191,241 74.56 0.0234
2025-08-14 2025-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,733,722 95,814 5.85 109,554 26.27 0.0149
2025-06-27 2025-03-31 13F/A-2 RHYTHM PHARMACEUTICALS CMN 76243J105 1,637,908 -174,298 -9.62 86,760 -14.48 0.0140
2025-05-16 2025-03-31 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 1,637,908 -174,298 86,760 0.0036
2025-05-09 2025-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,637,908 -174,298 86,760 0.0026
2025-02-11 2024-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,812,206 -2,067,590 -53.29 101,447 -50.09 0.0160
2024-11-14 2024-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 3,879,796 -1,408,839 -26.64 203,263 -6.40 0.0327
2024-08-13 2024-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,288,635 177,034 3.46 217,151 -1.96 0.0367
2024-05-15 2024-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,111,601 63,667 1.26 221,486 -4.55 0.0393
2024-05-14 2023-12-31 13F/A-2 RHYTHM PHARMACEUTICALS CMN 76243J105 5,047,934 -112,607 -2.18 232,054 96.15 0.0428
2024-03-01 2023-12-31 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 5,047,934 -112,607 232,054 0.0416
2024-02-13 2023-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,047,934 -112,607 232,054 0.0110
2024-05-15 2023-09-30 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 5,160,541 -25,472 -0.49 118,305 38.34 0.0252
2023-11-14 2023-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,160,541 -25,472 118,305 0.0238
2024-05-14 2023-06-30 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 5,186,013 -124,690 -2.35 85,517 -9.74 0.0183
2023-08-15 2023-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,186,013 -124,690 85,517 0.0172
2024-05-14 2023-03-31 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 5,310,703 108,911 2.09 94,743 -37.45 0.0218
2023-05-11 2023-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,310,703 108,911 94,743 0.0202
2024-05-14 2022-12-31 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 5,201,792 424,614 8.89 151,476 129,366.67 0.0371
2023-02-13 2022-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 5,201,792 424,614 151,476 0.0339
2024-05-14 2022-09-30 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 4,777,178 1,616,792 51.16 117 800.00 0.0296
2022-11-14 2022-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 4,777,178 1,616,792 117,040 0.0271
2024-05-14 2022-06-30 13F/A-2 RHYTHM PHARMACEUTICALS CMN 76243J105 3,160,386 -179,364 -5.37 13 -99.97 0.0033
2022-08-18 2022-06-30 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 3,160,386 -179,364 13,116 0.0030
2022-08-15 2022-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 3,160,386 -179,364 13,116 0.0030
2022-05-16 2022-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 3,339,750 243,202 7.85 38,474 24.50 0.0081
2022-02-17 2021-12-31 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 3,096,548 191,229 6.58 30,904 -18.55 0.0061
2022-02-14 2021-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 3,096,548 191,229 30,904 0.0018
2022-01-20 2021-09-30 13F/A-1 RHYTHM PHARMACEUTICALS CMN 76243J105 2,905,319 1,837,108 171.98 37,943 81.42 0.0080
2021-11-10 2021-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 2,905,319 1,837,108 37,943 0.0023
2021-08-13 2021-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 1,068,211 409,057 62.06 20,915 49.17 0.0047
2021-05-17 2021-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 659,154 606,742 1,157.64 14,021 799.94 0.0035
2021-02-12 2020-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 52,412 -3,856 -6.85 1,558 27.81 0.0004
2020-11-13 2020-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 56,268 23,195 70.13 1,219 65.18 0.0003
2020-08-12 2020-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 33,073 -18,841 -36.29 738 -6.58 0.0002
2020-05-15 2020-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 51,914 -12,927 -19.94 790 -46.94 0.0003
2020-02-14 2019-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 64,841 12,949 24.95 1,489 32.95 0.0004
2019-11-14 2019-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 51,892 -3,952 -7.08 1,120 -8.87 0.0003
2019-08-14 2019-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 55,844 8,878 18.90 1,229 -4.51 0.0004
2019-05-15 2019-03-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 46,966 26,935 134.47 1,287 139.22 0.0004
2019-02-14 2018-12-31 13F RHYTHM PHARMACEUTICALS CMN 76243J105 20,031 9,561 91.32 538 76.39 0.0002
2018-11-14 2018-09-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 10,470 2,952 39.27 305 29.79 0.0001
2018-08-14 2018-06-30 13F RHYTHM PHARMACEUTICALS CMN 76243J105 7,518 7,518 235 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.